A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...